Literature DB >> 3818094

Production and characterization of serovar-specific monoclonal antibodies to serovars 4, 8, and 9 of Mycobacterium intracellulare.

K Nishimori, H Yugi, M Naiki, T Sugimura, Y Tanaka, I Nonomura, Y Yokomizo, S Kubo.   

Abstract

Serovar-specific monoclonal antibodies against Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum complex serovars 4, 8, and 9 were prepared. Nine, four, and one monoclonal antibodies, respectively, to the serovars were prepared by the usual cell fusion technique. All nine monoclonal antibodies to serovar 4 were monospecific for their homologous serovar and reacted with several native glycopeptidolipids (GPLs) and one major deacylated GPL from the homologous serovar. One of the four monoclonal antibodies to serovar 8 seemed to be monospecific for its homologous serovar, but the other cross-reacted with serovar 6 because serovar 6 organisms contain the same components as does the major deacylated GPL from serovar 8. One monoclonal antibody to serovar 9 was monospecific for its homologous serovar and reacted with one of the two major deacylated GPLs from this serovar. These antibody preparations proved useful for serovar identification.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3818094      PMCID: PMC260398          DOI: 10.1128/iai.55.3.711-715.1987

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Isolation of mycobacteria from lymph nodes of pigs and their environment.

Authors:  S Masaki; K Shimizu; N Cho; T Hirose
Journal:  Nihon Juigaku Zasshi       Date:  1982-04

2.  Sensitive enzyme-immunostaining and densitometric determination on thin-layer chromatography of N-glycolylneuraminic acid-containing glycosphingolipids, Hanganutziu-Deicher antigens.

Authors:  H Higashi; Y Fukui; S Ueda; S Kato; Y Hirabayashi; M Matsumoto; M Naiki
Journal:  J Biochem       Date:  1984-05       Impact factor: 3.387

3.  Human cancer-associated gangliosides defined by a monoclonal antibody (IB9) directed to sialosyl alpha 2 leads to 6 galactosyl residue: a preliminary note.

Authors:  S Hakomori; E Nudelman; S B Levery; C M Patterson
Journal:  Biochem Biophys Res Commun       Date:  1983-06-29       Impact factor: 3.575

4.  Two monoclonal anticarbohydrate antibodies directed to glycosphingolipids with a lacto-N-glycosyl type II chain.

Authors:  W W Young; J Portoukalian; S Hakomori
Journal:  J Biol Chem       Date:  1981-11-10       Impact factor: 5.157

5.  Thin-layer chromatography of lipid antigens as a means of identifying nontuberculous mycobacteria.

Authors:  P J Brennan; M Heifets; B P Ullom
Journal:  J Clin Microbiol       Date:  1982-03       Impact factor: 5.948

6.  A monoclonal antibody reacting specifically with ganglioside GD1b in human brain.

Authors:  P Fredman; S Jeansson; E Lycke; L Svennerholm
Journal:  FEBS Lett       Date:  1985-09-09       Impact factor: 4.124

7.  Enzyme-linked immunosorbent assay of glycolipid antigens for identification of mycobacteria.

Authors:  D L Yanagihara; V L Barr; C V Knisley; A Y Tsang; J K McClatchy; P J Brennan
Journal:  J Clin Microbiol       Date:  1985-04       Impact factor: 5.948

8.  Immunogenicity of type-specific C-mycoside glycopeptidolipids of mycobacteria.

Authors:  W W Barrow; P J Brennan
Journal:  Infect Immun       Date:  1982-05       Impact factor: 3.441

9.  A monoclonal antibody recognizes an O-acylated sialic acid in a human melanoma-associated ganglioside.

Authors:  D A Cheresh; A P Varki; N M Varki; W B Stallcup; J Levine; R A Reisfeld
Journal:  J Biol Chem       Date:  1984-06-25       Impact factor: 5.157

10.  Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells.

Authors:  R Kannagi; N A Cochran; F Ishigami; S Hakomori; P W Andrews; B B Knowles; D Solter
Journal:  EMBO J       Date:  1983       Impact factor: 11.598

View more
  8 in total

Review 1.  Antigens of the Mycobacterium avium, Mycobacterium intracellulare complex.

Authors:  S L Morris
Journal:  Eur J Epidemiol       Date:  1991-07       Impact factor: 8.082

Review 2.  Immunological study of the defined constituents of mycobacteria.

Authors:  J Ivanyi; K Sharp; P Jackett; G Bothamley
Journal:  Springer Semin Immunopathol       Date:  1988

3.  Production and characterization of monoclonal antibodies against specific serotypes of Mycobacterium avium and the Mycobacterium avium-Mycobacterium intracellulare-Mycobacterium scrofulaceum complex.

Authors:  A H Kolk; R Evers; D G Groothuis; H Gilis; S Kuijper
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

4.  Generation of monoclonal antibodies to the specific sugar epitopes of Mycobacterium avium complex serovars.

Authors:  B Rivoire; B J Ranchoff; D Chatterjee; H Gaylord; A Y Tsang; A H Kolk; G O Aspinall; P J Brennan
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

5.  Distinctive western blot antibody patterns induced by infection of mice with individual strains of the Mycobacterium avium complex.

Authors:  A Elsaghier; A Nolan; B Allen; J Ivanyi
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

6.  Distribution of IS901 in strains of Mycobacterium avium complex from swine by using IS901-detecting primers that discriminate between M. avium and Mycobacterium intracellulare.

Authors:  K Nishimori; M Eguchi; Y Nakaoka; Y Onodera; T Ito; K Tanaka
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

7.  Production and analysis of specific monoclonal antibodies against the cell wall of Mycobacterium avium.

Authors:  S Wagner; U Klause; H Mauch
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

8.  Production, characterization, and species specificity of monoclonal antibodies to Mycobacterium avium complex protein antigens.

Authors:  D A Rouse; S L Morris; A B Karpas; P G Probst; S D Chaparas
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.